Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: A Phase II Trial
Chang et al., CROI 2025, Mar 2025
RCT 135 patients with mild to moderate COVID-19 showing significant efficacy of aerosolized siRNA SNS812 in reducing viral load and accelerating symptom resolution. The trial randomized patients to 200mg, 100mg, or placebo arms, with treatment initiated within 3 days of symptom onset. The 200mg group demonstrated significantly faster viral clearance and greater viral load reduction starting from day 1. Symptom improvement showed dose-dependent effects with significant reduction in time to resolution for 6 of 14 symptoms, including shortness of breath and loss of taste/smell. Authors do not provide enough information on symptomatic outcomes for meta analysis. The siRNA targets a highly conserved region of the viral RNA-dependent RNA polymerase gene and showed efficacy against multiple Omicron variants.
|
viral load, 17.1% lower, relative load 0.83, p = 0.01, treatment mean 2.98 (±1.14) n=45, control mean 2.47 (±1.14) n=45, day 4.
|
|
viral load, 13.3% lower, relative load 0.87, p = 0.13, treatment mean 2.85 (±1.19) n=44, control mean 2.47 (±1.14) n=45, day 4.
|
|
time to viral-, 19.4% lower, relative time 0.81, p = 0.007, treatment 45, control 45.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Chang et al., 11 Mar 2025, Double Blind Randomized Controlled Trial, Taiwan, peer-reviewed, 4 authors, study period 30 October, 2023 - 12 August, 2024, 100 mg$c$ mid-recovery.
Contact: erdrcsy@gmail.com.
